Physician profile
Muhammad Raza
NPI 1851607303
$13,670.80
in general payments reported to CMS, 2019-2025
30 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $246 · 2021: $260 · 2022: $272 · 2023: $527 · 2024: $11K · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,595.30 |
| Food and Beverage | $2,027.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,042.30 | 2024-2025 | Symplicity G3, Ffrangio, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $369.71 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $339.28 | 2020-2025 | |
| Boston Scientific Corporation | $242.49 | 2019-2025 | Watchman Flx, Varithena Administration Pack |
| Pfizer INC. | $239.50 | 2019-2025 | |
| Shockwave Medical, INC | $182.43 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $139.50 | 2021-2025 | Biomonitor |
| Abiomed | $132.43 | 2024-2025 | Impella |
| Angiodynamics, INC. | $105.23 | 2023 | Auryon Laser System 100-120 Vac |
| Astrazeneca Pharmaceuticals LP | $101.25 | 2020-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.31 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $92.70 | 2021-2023 | Verquvo |
| Abbott Laboratories | $84.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.99 | 2023-2024 | Camzyos, Eliquis |
| Terumo Medical Corporation | $62.86 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.13 | 2019-2023 | Jardiance |
| Cvrx, INC. | $39.75 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $31.74 | 2023 | |
| Esperion Therapeutics, INC. | $30.37 | 2023-2025 | Nexletol |
| Cardiovascular Systems INC. | $29.77 | 2019 | |
| Amarin Pharma, INC. | $28.85 | 2019-2020 | |
| Teleflex LLC | $28.40 | 2023 | Guideliner |
| Kiniksa Pharmaceuticals International, Plc | $19.00 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $18.19 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.40 | 2024 | Amvuttra |
| Biohorizons Implant Systems INC. | $16.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.45 | 2025 | |
| Medtronic Vascular, INC. | $14.79 | 2019 | |
| Astellas Pharma US INC | $14.54 | 2019 | |
| Watermark Medical, INC. | $13.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.